These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 36978204)
1. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Wang S; Zhao X; Wu S; Cui D; Xu Z Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204 [TBL] [Abstract][Full Text] [Related]
2. The role of myeloid-derived suppressor cells in hematologic malignancies. Gunes EG; Rosen ST; Querfeld C Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593 [TBL] [Abstract][Full Text] [Related]
3. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Bhardwaj V; Ansell SM Front Cell Dev Biol; 2023; 11():1129343. PubMed ID: 37091970 [TBL] [Abstract][Full Text] [Related]
4. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. De Cicco P; Ercolano G; Ianaro A Front Immunol; 2020; 11():1680. PubMed ID: 32849585 [TBL] [Abstract][Full Text] [Related]
5. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. Zhao Y; Du J; Shen X Front Immunol; 2023; 14():1157537. PubMed ID: 37006306 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Fan R; De Beule N; Maes A; De Bruyne E; Menu E; Vanderkerken K; Maes K; Breckpot K; De Veirman K Front Immunol; 2022; 13():1016059. PubMed ID: 36304465 [TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Wu Y; Yi M; Niu M; Mei Q; Wu K Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047 [TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. Lu LC; Chang CJ; Hsu CH J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667 [TBL] [Abstract][Full Text] [Related]
9. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Hou A; Hou K; Huang Q; Lei Y; Chen W Front Immunol; 2020; 11():783. PubMed ID: 32508809 [TBL] [Abstract][Full Text] [Related]
10. Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy. Bullock K; Richmond A Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944914 [TBL] [Abstract][Full Text] [Related]
11. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545 [TBL] [Abstract][Full Text] [Related]
13. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells. Lim J; Lee A; Lee HG; Lim JS Biomol Ther (Seoul); 2020 Jan; 28(1):1-17. PubMed ID: 31431006 [TBL] [Abstract][Full Text] [Related]
14. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies. Sun W; Hu S; Wang X Cancer Commun (Lond); 2024 Sep; 44(9):1071-1097. PubMed ID: 39073258 [TBL] [Abstract][Full Text] [Related]
15. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target. J Clin Invest; ; . PubMed ID: 37395271 [TBL] [Abstract][Full Text] [Related]